Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2982772 in Moderate to Severe Plaque Psoriasis
NCT04316585Phase 1Completed
- Sponsor
- GSK
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in plaque psoriasis comparing GSK2982772 960 mg with Placebo (2 arms). Primary endpoint: Percentage of Participants Who Achieved >= 75% Improvement From Baseline in Psoriasis Area Severity Index (PASI) Score at 12 weeks. Started Sep 2020; status: completed.
02
Drugs
GSK2982772
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04316585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316585.